International journal of cardiology · 2025
Genotype-negative hypertrophic cardiomyopathy: Exploring the role of cardiovascular risk factors in disease expression.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schoonvelde Stephan A C, Nollet Edgar E, Zwetsloot Peter-Paul, Knackstedt Christian, Germans Tjeerd, Hirsch Alexander, Schinkel Arend F L, van Slegtenhorst Marjon A, Verhagen Judith M A, de Boer Rudolf A, van der Velden Jolanda, Michels Michelle
Аннотация
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common inherited myocardial disease. An inheritable cause is identified in approximately half of patients. Earlier research has identified clinical differences between genotype-positive (G+) and genotype-negative (G-) HCM patients, which this study aimed to further explore.
METHODS AND RESULTS: Differences in baseline characteristics, including cardiovascular risk factors (CVRF), and phenotypical factors between G+ and G- patients were explored. Subanalyses among distinct age groups and sexes were performed. A total of 422 HCM (46 % G-, 54 % G+) patients were included. G- patients were older (62 vs 54 years, p < 0.001), experienced more limiting cardiac symptoms (47 % vs 28 %, p = 0.008), and more frequent left ventricular outflow tract obstruction (57 % vs 38 %, p < 0.001). CVRF were more prevalent in G- than in G+ HCM patients (70 % vs 41 %, p < 0.001), with hypertension being the most prevalent factor (51 % vs 22 %, p < 0.001). Despite adjusting for patient age, CVRF presence significantly predicted G- classification (OR 2.3, 95 %CI 1.5-3.6, p < 0.001). Female G- patients were less prevalent in younger age groups, and only in the older age group (>60 years) were female G- patients diagnosed later than their G+ counterparts.
CONCLUSION: CVRF, particularly hypertension, are more prevalent in G- patients independent of age, suggesting that cardiovascular health may contribute to HCM disease development. Male-female differences suggest female-specific factors affecting the development of HCM in women. Recognizing G- HCM as a distinct clinical entity may have important implications for patient management, and a more comprehensive understanding of its aetiology may aid in tailoring future therapies.
METHODS AND RESULTS: Differences in baseline characteristics, including cardiovascular risk factors (CVRF), and phenotypical factors between G+ and G- patients were explored. Subanalyses among distinct age groups and sexes were performed. A total of 422 HCM (46 % G-, 54 % G+) patients were included. G- patients were older (62 vs 54 years, p < 0.001), experienced more limiting cardiac symptoms (47 % vs 28 %, p = 0.008), and more frequent left ventricular outflow tract obstruction (57 % vs 38 %, p < 0.001). CVRF were more prevalent in G- than in G+ HCM patients (70 % vs 41 %, p < 0.001), with hypertension being the most prevalent factor (51 % vs 22 %, p < 0.001). Despite adjusting for patient age, CVRF presence significantly predicted G- classification (OR 2.3, 95 %CI 1.5-3.6, p < 0.001). Female G- patients were less prevalent in younger age groups, and only in the older age group (>60 years) were female G- patients diagnosed later than their G+ counterparts.
CONCLUSION: CVRF, particularly hypertension, are more prevalent in G- patients independent of age, suggesting that cardiovascular health may contribute to HCM disease development. Male-female differences suggest female-specific factors affecting the development of HCM in women. Recognizing G- HCM as a distinct clinical entity may have important implications for patient management, and a more comprehensive understanding of its aetiology may aid in tailoring future therapies.